GovChime
AWARDDELIVERY ORDEROther than small business

Delivery order 75N91023F00002THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER

Overview

Award facts

Net obligations
$1.25M
$1,249,115of $1.25M potential value
Outlays (paid to date)
$1.02M
$1.02M paid of $1.25M obligated$1,015,762
Period of performance
Jun 26, 2023 to Oct 25, 2026
Ended
Modifications
5
Latest action Mar 9, 2026
Contract type
Delivery order
PIID 75N91023F00002

Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.

Description of requirement

TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA

Dates and value

Award date
Signed on Jun 20, 2023
Potential end of performance
Oct 24, 2026
Current value
$1,249,115Base and exercised options
Potential value (if all options are exercised)
$1,249,115
Parent contract vehicle
75N91019D00021 (IDC, multiple award) — 13 orders recorded under it

Obligations by fiscal year of action

  • FY2024: $147,621
  • FY2023: $1,101,494

Total across 2 fiscal years: $1,249,115

Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Mar 9, 2026. View on USAspending · Recipient on SAM.gov

Recipient

NameTHE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER
LocationHOUSTON, TX
UEIS3GMKS8ELA16
CAGE code0KD38
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeUS government entity
Parent companyTHE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER

Business types and certifications

Educational institutionU.S. government entity

Self-reported at the time of the action.

Agency and place

Awarding and funding

Awarded by
  1. Department of Health and Human Services
  2. National Institutes Of Health
  3. NIH NCI
Funded by
  1. Department of Health and Human Services
  2. National Institutes Of Health
  3. NIH NCI
Funded from
National cancer institute (0849)Program activities075-0849Federal accounts (agency financial reports)

Place of performance

Place of performance
Houston, Harris County, Texas 77030-4009
Congressional district (place of performance)
TX-09As reported at the time of the action

Classification and competition

Classification

NAICS
541714RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Product or service (PSC)
AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)

Competition

Extent competed
Full and open competitionA
Solicitation procedures
Subject to multiple award fair opportunityMAFO
Set-aside
Not reported
Contract pricing
Firm fixed priceJ
Offers received
1

Solicitation and notices

Solicitation ID
TORFP 2023 E-02(as reported)
Solicitation date
Jan 20, 2023

Contract details

Subcontracting plan
Individual subcontract planF
Major program
Prevent preclinical drug development program: preclinical efficacy & intermediate biomarkers
Cost Accounting Standards clause
Yes - CAS clause includedY
Certified cost or pricing data
No
Commercial procedures
Commercial products/services procedures not usedD
Government-furnished property
Transaction does not use GFE/GFPN
Bundled requirement
Not bundledH
Consolidated requirement
Not consolidatedD
Undefinitized action (terms not final)
No
Multi-year contract
No
Performance-based service acquisition
No - service where PBA is not used.N

Transaction history

Modification history

Base award
Jun 20, 2023Base obligation at award: $1,101,494
Latest action
Mar 9, 2026 — Supplemental agreement (within scope)Modification P00005
Latest substantive action
Mar 9, 2026 — Supplemental agreement (within scope)Modification P00005
Actions by type
  • Base award1
  • Supplemental agreement (within scope)3
  • Change order1
  • Other administrative action1
6 actions recorded, Jun 20, 2023 to Mar 9, 2026; each action counted once.

All contract data

All contract data

Every other field reported for this award, as of its latest reported action

Competition

Evaluation preference
No preference used
Local area set-aside
No
Synopsized publicly (SAM.gov / FedBizOpps)
Yes
Simplified procedures for commercial items
No
A-76 (FAIR Act) action
No

Pricing and financing

Paid by purchase card
No

Socio-economic and policy

Inherently governmental functions
Other functionsOT
Recovered materials and sustainability
No clauses included and no sustainability includedC
EPA-designated product
Not requiredE
Clinger-Cohen Act planning (IT)
No
Walsh-Healey Act (materials and supplies)
Yes

Place and origin

Domestic or foreign entity
Other U.S. entity (e.g. government)B
Country of product or service origin
United statesUSA
Place of manufacture
Not a manufactured end productC

Structure

Award or IDV
Award
Award type
Delivery orderC
Parent vehicle type
IDCB
Parent vehicle: multiple or single award
Multiple awardM
Parent vehicle agency
National Institutes Of Health7529
Awarding agency code
7500
Awarding sub-tier code
7529
Contracting office code
75N910
Transactions recorded under this award key
6

Funding

Funding agency code
7500
Funding sub-tier code
7529
Funding office code
75N910
Treasury accounts
  • 075-2023/2023-0849-000
  • 075-2025/2025-0849-000
Object classes
  • 25.5: Research and development contracts
Disaster or emergency funding (DEFC)
  • Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression